Alize Pharma initiates AZP-531 Phase We medical trial for treatment of type 2 diabetes The Medicine and Healthcare Regulatory Authority has granted authorization to conduct a trial in the UK on AZP-531 in healthy volunteers, obese subjects and diabetics Alize Pharma, a company specialized in the development of drugs for the treating metabolic diseases and rare diseases, announces today the start of the first Stage I clinical trial for AZP-531, its unacylated ghrelin analog, in type 2 diabetes. The Medicines and Healthcare Regulatory Agency , the body that regulates medicines and healthcare products in the united kingdom, has certified this trial that’ll be conducted as a combined Phase Ia and Phase Ib protocol. The clinical trial is set to last approximately 1 eddrugs2018.com .
Alimera receives FDA CRL for ILUVIEN NDA pSivida Corp.S. Food and Medication Administration regarding its New Drug Application for ILUVIEN. The FDA issued the CRL to communicate its decision that the NDA can’t be authorized in its present form. Related StoriesInnovation in anaesthesia: an interview with Matti Lehtonen, GE HealthcareLiposomal sizing and the Coulter principle: an interview with Professor Melvin E. KlegermanExpanded make use of for IntelliCap with further CE Tag for aspiration of fluidsThe NDA seeks approval to market ILUVIEN , an investigational, sustained drug delivery system that releases sub-microgram levels of fluocinolone acetonide for the treating DME.